Glimepiride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Glimepiride: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome
One-Sentence Summary
Glimepiride is a sulfonylurea originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for focal stiff limb syndrome, but 0 clinical trials and 0 publications currently support this prediction, so it rests on the model's graph-based score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (taken from the drug's knowledge-graph indications, because the Singapore registrations do not state an approved indication) |
| Predicted New Indication | Focal stiff limb syndrome |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on general pharmacology, glimepiride is a sulfonylurea that closes ATP-sensitive potassium (K-ATP) channels on pancreatic beta cells to stimulate insulin release. Its efficacy in type 2 diabetes is well established.
A mechanistic link to focal stiff limb syndrome has not been established. This condition belongs to the stiff-limb/stiff-person spectrum, which is often linked to anti-GAD65 autoimmunity and GABAergic dysfunction. A likely reason for the prediction is that this spectrum frequently co-occurs with diabetes, so the two sit close together in the knowledge graph. That is an indirect association and not evidence that glimepiride treats the condition. The related prediction, classic stiff person syndrome, scored identically and has the same weakness.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
All 5 registrations are valid single-ingredient oral tablets.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| SIN10459P | AMARYL 2.0 TABLETS 2 mg | Tablet | SANOFI SRL |
| SIN10460P | AMARYL 1.0 TABLETS 1 mg | Tablet | SANOFI SPA |
| SIN10462P | AMARYL 3.0 TABLETS 3 mg | Tablet | SANOFI SPA |
| SIN13674P | DIALOSA TABLET 3MG | Tablet | PharmaPath SA |
| SIN13675P | DIALOSA TABLET 2MG | Tablet | PharmaPath SA |
Safety Considerations
The package insert warnings and contraindications were not available for this report. Please refer to the package insert for authoritative safety information.
- Conditions flagged in the knowledge graph (not label text): kidney disease, liver disease, gallbladder disease, congestive heart failure, pituitary hormone deficiency (including hypopituitarism and Sheehan syndrome), hypogonadotropic hypogonadism (including Kallmann syndrome), thymus gland disease, osteoporosis (including postmenopausal), and infectious disease.
- Drug interactions: 100 interactions were identified, mostly Moderate and some Minor. Examples at Moderate level include:
- Beta-agonists and sympathomimetics: phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol.
- Other drugs: acebutolol, famotidine, ranitidine, acetazolamide, ibuprofen, ketorolac, hydrochlorothiazide, ethinylestradiol, hydrocortisone, albiglutide, acitretin, nitazoxanide, ethanol.
- Minor-level examples: topical hydrocortisone and topical alclometasone.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but no trials or publications support it, and no plausible mechanism links a glucose-lowering sulfonylurea to focal stiff limb syndrome. The evidence is model prediction only (L5).
To proceed, the following is needed:
- A literature and mechanism review to test whether any biological link exists, such as GABAergic or autoimmune pathways.
- Mechanism of action data for glimepiride.
- The package insert warnings and contraindications.
- A safety plan covering hypoglycaemia risk in non-diabetic patients and the interactions listed above.
- Consideration of other predicted indications, such as type 1 diabetes mellitus (L2 on current data). The listed trials there mostly enrolled type 2 diabetes patients, so their relevance still needs confirmation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.